Project Grant R01AI179691

Award Date 6/11/24
Completion Date 4/30/29
Dollars Obligated $2.1M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award, valued at $136,350.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID, CFDA 93.855 Allergy and Infectious Diseases Research), aims to understand how HIV-1 packages its RNA genome during virus assembly. The primary objectives are to: (I) identify the structural determinants and mechanism of the Gag polyprotein assembly on the viral RNA packaging signal, and (II) collect structural information on the host cell factor Staufen1 interaction...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $400,125.00 to Meharry Medical College to elucidate a novel mechanism by which HIV-1 evades the antiviral activity of the host protein APOBEC3G. The research aims to: 1) compare APOBEC3G-related mutation profiles in HIV-infected cells and released virions, focusing on key viral RNA packaging elements, and 2)...
This $219,117 federal Project Grant award from the National Science Foundation (NSF) Biological Sciences (CFDA 47.074) program supports research into the role of RNA structure in the packaging and discovery of RNA bacteriophage genomes at San Diego State University Foundation. The project aims to investigate how the RNA genomes of bacteriophages (viruses that infect bacteria) are packaged into their protein capsids, focusing on identifying the specific RNA structures involved in this selective...
This Project Grant award of $847,141 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into the non-catalytic role of HIV-1 integrase (IN) during virion morphogenesis, as well as the mechanism of action of the investigational HIV-1 inhibitor drug pirmitegravir. The research aims to delineate the sequence and structural features of viral RNA recognized by HIV-1 IN, determine cryo-EM...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) is providing $257,429 to the University of Miami to develop strategies to prevent or eliminate immune responses to adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (bnAbs) for HIV prevention and treatment. The key objectives are to: 1) Attempt to induce tolerance toward AAV-delivered bnAbs using a synergistic drug treatment regimen of rapamycin...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $854,360.00 to support research on understanding the role of HIV RNA modifications in chronic inflammation for people living with HIV on antiretroviral therapy. The research aims to identify the molecular mechanisms linking HIV RNA modifications to innate immune activation in HIV-infected macrophages, as well...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to uncover the underlying mechanism of the innate immune effector TRIM56's antiviral activity, with a focus on HIV-1. The $154,568 award, running from May 2025 to November 2027, will enable the principal investigator to: (1) investigate whether TRIM56 directly binds the HIV-1 RNA genome, thereby blocking...
This $370,190 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), aims to measure and understand the molecular mechanisms of viral nucleocapsid self-assembly and disassembly. The research will apply quantitative experimental methods, including interferometric scattering microscopy and cryo-electron microscopy, to a diverse set of RNA-packaging viruses. The goal is to uncover potentially...
This $474,620 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research at the University of California, San Francisco (UCSF) to comprehensively define the selective pressures and evolutionary potential of the HIV-1 capsid. The goal is to better understand how HIV evades human cell-intrinsic restriction factors, with the aim of informing the design of capsid-targeting...
This Project Grant award, titled "The Role of FEZ Protein Homologs in Early HIV-1 Infection," is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary awardee is Northwestern University, which will receive $714,754 over the award period from November 2024 to October 2029. The project aims to develop a detailed structural and functional understanding of how FEZ family proteins,...

SELECTIVE PACKAGING AND PROTECTION OF HIV-1 GENOMIC RNAS - ABSTRACT VIRTUALLY EVERY STEP OF HIV-1 REPLICATION AS WELL AS NUMEROUS CELLULAR ANTIVIRAL DEFENSE MECHANISMS ARE REGULATED BY VIRAL AND CELLULAR RNA-BINDING PROTEINS (RBPS) THAT RECOGNIZE DISTINCT SEQUENCE OR STRUCTURAL FEATURES ON VIRAL RNAS. ONE SUCH INTERACTION TAKES PLACE BETWEEN THE HIV-1 MAJOR STRUCTURAL PROTEIN, GAG, AND THE VIRAL GENOMIC RNA (GRNA). THROUGH ITS NUCLEOCAPSID (NC) DOMAIN, GAG SELECTS TWO COPIES OF AN UNSPLICED POSITIVE STRAND GRNA FROM A POOL OF CELLULAR AND SPLICED VIRAL MRNAS IN EXCESS AND ORCHESTRATES KEY STEPS OF VIRION ASSEMBLY. HOW GRNAS ARE SELECTED FOR PACKAGING, WHY ONLY A DIMER IS PACKAGED IN A SINGLE VIRUS PARTICLE AND WHETHER NC-GRNA INTERACTIONS GUIDE OTHER RBPS THAT TARGET THE SAME GRNA REMAIN POORLY UNDERSTOOD. PREVIOUS CLIP STUDIES DEMONSTRATED THAT GAG PREDOMINANTLY BINDS TO GUANOSINE-RICH SEQUENCES IN THE CYTOSOL, BUT ITS BINDING PREFERENCE SHIFTS TOWARDS SEQUENCES WITH ADENOSINE-RICH NUCLEOTIDE COMPOSITION (INCLUDING BINDING SITES ON CELLULAR MRNAS) AT THE PLASMA MEMBRANE WHERE VIRIONS ASSEMBLE. HERE WE PROPOSE TO FORMALLY TEST WHETHER ADENOSINE-RICHNESS OF THE HIV-1 GRNA FACILITATES ITS SELECTIVE PACKAGING THROUGH COMPLEMENTARY GENETIC AND BIOCHEMICAL APPROACHES (AIM 1). ACCORDING TO A WIDELY ACCEPTED MODEL, RECRUITMENT OF A DIMERIC GRNA TO THE PLASMA MEMBRANE NUCLEATES VIRION ASSEMBLY, RESULTING IN PROGRESSIVE RECRUITMENT OF GAG MOLECULES FROM THE CYTOSOL. AS THE LATE ARRIVING POOL OF GAG MOLECULES AT THE NUCLEATION SITE NEEDS TO BE DEVOID OF RNAS, WE HYPOTHESIZE THAT AFFINITY OF GAG TOWARDS COGNATE RNAS IS A KEY PARAMETER THAT UNDERPINS DIMERIC GRNA PACKAGING. IN AIM 2, WE PROPOSE TO DISRUPT THIS BALANCE BY GENERATING GAG CHIMERAS WITH ALTERED AFFINITY/AVIDITY TOWARDS TARGET RNAS AND DETERMINE THE IMPACT ON DIMERIC GRNA TRAFFICKING TO THE PM, GRNA PACKAGING AND VIRUS PARTICLE ASSEMBLY. IN AIM 3, USING THE GAG CHIMERIC VIRUSES AS TOOLS, WE PROPOSE TO TARGET KEY NC FUNCTIONS AND DETERMINE THE NC- AND GRNA-DEPENDENCE OF OTHER VIRAL AND HOST RBPS THAT ARE CRITICAL REGULATORS OF HIV-1 REPLICATION AND HOST DEFENSES. SPECIFICALLY, WE PROPOSE TO EXAMINE WHETHER MEMBERS OF THE ANTIVIRAL APOBEC3 PROTEIN FAMILY INFILTRATE INTO VIRIONS THROUGH BINDING TO THE VIRAL GRNA OR OTHER VIRION- INCORPORATED HOST RNAS, SUCH AS 7SL. AS PART OF THIS AIM, GAG CHIMERAS THAT CAN PACKAGE GRNA INDEPENDENT OF NC WILL BE USED TO TEST THE DEPENDENCE OF INTEGRASE-GRNA BINDING, AN EVENT CRITICAL FOR PROPER VIRION MATURATION, ON NC AND NC-GRNA INTERACTIONS. UNDERSTANDING THE INTERPLAY BETWEEN MULTIPLE RBPS THAT TARGET THE SAME GRNA IS HIGHLY RELEVANT TO OUR FUNDAMENTAL UNDERSTANDING OF HIV-1 REPLICATION AND VIRUS-HOST INTERACTIONS. CURRENTLY, NO ANTIRETROVIRALS TARGET GRNA PACKAGING AND ASSEMBLY DESPITE THESE STEPS PRESENTING A CLEAR VULNERABILITY FOR HIV-1. OUR PRELIMINARY STUDIES DEMONSTRATE THAT GAG-GRNA INTERACTIONS ARE FINELY TUNED AND CAN BE TARGETED. PROPOSED WORK IS THUS SIGNIFICANT AS IT MAY GUIDE THE DEVELOPMENT OF NC- OR GRNA-TARGETED DRUGS THAT ABROGATE GRNA PACKAGING, VIRION ASSEMBLY AND INFECTIVITY.

Posted 6/11/24, 12:00 AM